Trials / Recruiting
RecruitingNCT04324125
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
Chemotherapy or Chemotherapy Plus PD-1 Antibody in HER 2 Insertion or Amplification Advanced Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
Detailed description
Main enrolled criteria: Her2 insertion advanced NSCLC Her 2 amplification advanced NSCLC Failed with standard chemotherapy No history of PD-1/ PD-L1 antibody using
Conditions
Timeline
- Start date
- 2020-03-24
- Primary completion
- 2024-12-24
- Completion
- 2025-03-24
- First posted
- 2020-03-27
- Last updated
- 2024-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04324125. Inclusion in this directory is not an endorsement.